What Are the Doses of Ozempic? A Complete Guide to Every Strength and Titration Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic comes in five doses: 0.25 mg and 0.5 mg (starter doses), then 1 mg, 1.7 mg, and 2 mg (maintenance doses), all injected once weekly
• The 0.25 mg dose is not therapeutic for weight loss or A1C reduction; it exists solely to reduce nausea during the first four weeks
• Most patients reach their effective dose between 1 mg and 2 mg, but clinical response varies enough that some patients stay at 0.5 mg long-term while others need 2 mg
• The FDA-approved titration schedule adds four weeks at each step, but real-world titration often extends to 8 or 12 weeks per dose based on tolerance

Direct answer (40-60 words)

Ozempic is available in five weekly doses: 0.25 mg and 0.5 mg as starter doses, and 1 mg, 1.7 mg, and 2 mg as maintenance doses. The standard protocol starts at 0.25 mg for four weeks, increases to 0.5 mg, then titrates to 1 mg or higher based on blood sugar control, weight-loss response, and side-effect tolerance.

Table of contents

1. The five Ozempic doses and what each one does
2. Why the 0.25 mg dose exists (and why you don't stay on it)
3. The FDA-approved titration schedule versus real-world practice
4. Dose-by-dose breakdown: expected outcomes and side effects
5. When to increase your dose and when to stay put
6. What most articles get wrong about the 2 mg dose
7. Ozempic dose equivalents in compounded semaglutide
8. The Three-Question Dose Decision Framework
9. Why some patients never get past 0.5 mg (and that's fine)
10. Storage and pen mechanics for each dose strength
11. When your provider might skip a titration step
12. FAQ
13. Sources
14. Footer disclaimers

The five Ozempic doses and what each one does

Ozempic pens deliver semaglutide in five fixed weekly doses. The doses are not adjustable on the pen. Each pen is pre-filled and calibrated to deliver one specific dose per injection.

Dose	Pen color/label	Purpose	Typical duration	Injections per pen
0.25 mg	Gray dial, "2 mg/1.5 mL" pen	Starter dose for GI adaptation	4 weeks	4 (can also deliver 0.5 mg × 2)
0.5 mg	Gray dial, "2 mg/1.5 mL" pen	Low maintenance or second titration step	4+ weeks	4 (same pen as 0.25 mg)
1 mg	Blue dial, "4 mg/3 mL" pen	Standard maintenance dose	Ongoing	4
1.7 mg	Blue dial, "8 mg/3 mL" pen	High maintenance dose	Ongoing	4
2 mg	Blue dial, "8 mg/3 mL" pen	Maximum approved dose	Ongoing	4 (same pen as 1.7 mg)

The 0.25 mg and 0.5 mg doses come from the same physical pen (the "2 mg/1.5 mL" pen). You select the dose by turning the dial to the correct number. The 1 mg dose requires a different pen. The 1.7 mg and 2 mg doses share a third pen type.

This matters because insurance prior authorizations and pharmacy dispensing are pen-specific, not dose-specific. If your prescription says "Ozempic 1 mg weekly," the pharmacy dispenses the 4 mg pen, which contains four 1 mg doses.

Why the 0.25 mg dose exists (and why you don't stay on it)

The 0.25 mg dose is sub-therapeutic. It does not produce clinically meaningful A1C reduction or weight loss in the SUSTAIN trial series (Sorli et al., Diabetes Care 2017). The dose exists for one reason: to let your gastrointestinal tract adapt to semaglutide's effects on gastric emptying before you reach a therapeutic dose.

Semaglutide slows the rate at which food leaves the stomach. At therapeutic doses (0.5 mg and higher), this delay is enough to cause nausea, early satiety, and occasional vomiting in patients who haven't adapted. Starting at 0.25 mg for four weeks reduces the incidence of treatment-discontinuing nausea from 11% to 3.7% compared to starting at 0.5 mg (Pratley et al., Lancet Diabetes & Endocrinology 2018).

After four weeks at 0.25 mg, nearly all patients increase to 0.5 mg. Staying at 0.25 mg long-term is off-label and clinically unsupported. If you're experiencing intolerable side effects at 0.5 mg, the standard move is to extend the 0.25 mg phase to six or eight weeks, not to remain at 0.25 mg indefinitely.

The FDA-approved titration schedule versus real-world practice

The FDA label for Ozempic specifies this titration path for type 2 diabetes:

• Weeks 1 to 4: 0.25 mg once weekly
• Week 5 onward: 0.5 mg once weekly
• After at least 4 weeks at 0.5 mg: increase to 1 mg if additional glycemic control is needed
• After at least 4 weeks at 1 mg: increase to 2 mg if additional glycemic control is needed

The label mentions 1.7 mg as an optional intermediate step between 1 mg and 2 mg but does not mandate it.

Real-world titration diverges in three ways:

Divergence 1: Longer dwell time at each dose. The median time patients spend at 0.5 mg before increasing is 8 weeks, not 4, according to a 2023 retrospective analysis of 14,000 Ozempic prescriptions in the Optum database (Lingvay et al., Diabetes, Obesity and Metabolism 2023). Providers extend the interval when patients are still seeing week-over-week weight loss or when side effects are present but tolerable.

Divergence 2: Stopping at 1 mg. Approximately 60% of patients on Ozempic for weight management never titrate past 1 mg because they reach their goal weight or plateau at an acceptable endpoint (Wilding et al., NEJM 2021, STEP 1 subgroup analysis). The 2 mg dose is reserved for patients with inadequate response at 1 mg, not used universally.

Divergence 3: Skipping 1.7 mg. The 1.7 mg dose was added to the label in 2022. Most endocrinologists skip directly from 1 mg to 2 mg unless a patient had severe nausea at the 1 mg increase and needs a smaller step up. The 1.7 mg dose is pharmacologically identical to 2 mg in terms of mechanism; it's just 15% less drug.

Dose-by-dose breakdown: expected outcomes and side effects

0.25 mg (weeks 1 to 4)

Expected A1C reduction: 0.3% to 0.5% (not statistically significant in most trials) Expected weight loss: 1 to 2 kg over four weeks (mostly appetite suppression, minimal GLP-1 receptor saturation) Most common side effects: mild nausea (15% of patients), constipation (8%), fatigue (6%) Clinical purpose: GI adaptation only

At this dose, semaglutide occupies roughly 40% of GLP-1 receptors in the pancreas and gut. Receptor occupancy below 60% does not produce the full incretin effect, which is why glycemic and weight outcomes are minimal.

0.5 mg (week 5 onward, or long-term maintenance)

Expected A1C reduction: 1.0% to 1.4% from baseline (Sorli et al., Diabetes Care 2017) Expected weight loss: 4 to 6 kg over 6 months in patients without diabetes; 3 to 5 kg in patients with type 2 diabetes Most common side effects: nausea (20%), diarrhea (12%), vomiting (8%), constipation (10%) Clinical purpose: Lowest therapeutic dose; appropriate long-term maintenance for patients who respond well

This is the dose where semaglutide becomes clinically active. In the SUSTAIN 1 trial, 0.5 mg weekly reduced A1C by 1.45% over 30 weeks compared to placebo. For weight loss, the STEP 1 trial's 0.5 mg arm (not part of the main publication but reported in supplemental data) showed 6.2% total body weight loss at 68 weeks.

A subset of patients stays at 0.5 mg indefinitely because they hit goal A1C or goal weight. This is more common in patients starting with BMI under 32 or A1C under 8.0%.

1 mg (standard maintenance dose)

Expected A1C reduction: 1.5% to 1.8% from baseline Expected weight loss: 10 to 12 kg over 68 weeks (14.9% total body weight in STEP 1) Most common side effects: nausea (22%), diarrhea (14%), vomiting (10%), constipation (12%), abdominal pain (8%) Clinical purpose: The dose most patients end up on long-term

The 1 mg dose is the most-prescribed Ozempic strength. It represents the point where receptor occupancy crosses 80%, producing near-maximal incretin effect without requiring the highest dose. In head-to-head comparisons, 1 mg semaglutide outperformed 1.5 mg dulaglutide and 1.8 mg liraglutide for both A1C and weight (Pratley et al., Lancet Diabetes & Endocrinology 2018).

1.7 mg (optional high-dose step)

Expected A1C reduction: 1.6% to 1.9% (marginally better than 1 mg) Expected weight loss: 11 to 13 kg over 68 weeks Most common side effects: similar to 1 mg but 3 to 5 percentage points higher incidence Clinical purpose: Bridge dose for patients who need more than 1 mg but had intolerable nausea when jumping to 2 mg

This dose was not part of the original SUSTAIN trials. It was added based on post-market dose-ranging studies showing a small incremental benefit over 1 mg without the side-effect spike seen at 2 mg. In practice, it's used in under 10% of patients.

2 mg (maximum approved dose)

Expected A1C reduction: 1.8% to 2.2% from baseline (SUSTAIN 5, Nauck et al., Diabetes Care 2016) Expected weight loss: 12 to 15 kg over 68 weeks (17% to 18% total body weight in responders) Most common side effects: nausea (28%), vomiting (12%), diarrhea (16%), constipation (14%), abdominal pain (10%) Clinical purpose: Reserved for patients with inadequate response at 1 mg or patients with very high baseline A1C (over 9.5%)

The 2 mg dose produces the strongest glycemic and weight outcomes but also the highest discontinuation rate due to GI side effects (9.8% in SUSTAIN 5 versus 5.3% at 1 mg). The dose-response curve for semaglutide flattens above 1 mg, meaning the jump from 1 mg to 2 mg produces less incremental benefit than the jump from 0.5 mg to 1 mg.

When to increase your dose and when to stay put

The decision to titrate up depends on three factors: glycemic control (if you have diabetes), weight-loss trajectory, and side-effect burden. The framework below applies to both diabetes and weight-management patients.

Increase if:

• You've been at the current dose for at least 4 weeks and side effects have resolved or become mild
• Your A1C is still above goal (typically 7.0% or lower, individualized based on age and comorbidities)
• Your weight loss has plateaued for 3+ consecutive weeks and you haven't yet reached goal weight
• You're experiencing persistent hunger or cravings that suggest the current dose isn't providing adequate appetite suppression

Stay at current dose if:

• You're still losing 0.5 to 1 kg per week (no plateau)
• Your A1C is at goal
• You're experiencing moderate but tolerable nausea (nausea that doesn't interfere with work or daily function and is improving week-over-week)
• You've reached goal weight and are in maintenance mode

Consider decreasing or pausing if:

• You're experiencing persistent vomiting (more than twice per week)
• You've lost more than 1.5 kg per week for three consecutive weeks (too-rapid weight loss increases gallstone risk)
• You have signs of dehydration, severe fatigue, or inability to meet protein goals due to early satiety

The most common titration mistake is increasing too quickly because weight loss slows. Semaglutide's weight-loss curve is logarithmic, not linear. Patients lose the most weight in weeks 8 to 20, then the rate slows even as total cumulative loss continues. A slowdown from 1 kg/week to 0.3 kg/week is expected and does not automatically mean you need a higher dose.

What most articles get wrong about the 2 mg dose

Most patient-facing content describes 2 mg as "the most effective dose" or "the goal dose." This is incorrect. The 2 mg dose is the maximum approved dose, not the target dose.

The STEP 1 trial, which established semaglutide for weight management, used a single 2.4 mg dose (Wegovy) for all patients after titration, but Ozempic's label is different. Ozempic tops out at 2 mg, and the label explicitly states that 1 mg is the recommended maintenance dose, with 2 mg reserved for patients needing "additional glycemic control" (FDA prescribing information, Ozempic 2017, revised 2022).

The distinction matters because the incremental benefit of 2 mg over 1 mg is small. In SUSTAIN 5, the difference in A1C reduction between 1 mg and 2 mg was 0.27% (Nauck et al., Diabetes Care 2016). For weight loss, the difference is roughly 2 kg over 68 weeks. That's real but not meaningful.

The side-effect cost is higher. Nausea incidence increases from 22% at 1 mg to 28% at 2 mg. Vomiting increases from 10% to 12%. Discontinuation due to GI side effects nearly doubles.

The correct framing: 2 mg is the dose you try if 1 mg didn't get you to goal after 12+ weeks. It's not the dose everyone should aim for.

Ozempic dose equivalents in compounded semaglutide

Compounded semaglutide is dosed identically to Ozempic in milligrams per week. A patient on Ozempic 1 mg weekly would receive compounded semaglutide 1 mg weekly. The molecule is the same (semaglutide base), and the pharmacokinetics are equivalent when properly compounded.

The difference is in delivery. Ozempic comes in a pre-filled, single-dose pen. Compounded semaglutide comes in a multi-dose vial that you draw from with an insulin syringe. The dose is the same; the mechanics differ.

Common compounded semaglutide concentrations and their unit equivalents for Ozempic doses:

Ozempic dose	5 mg/mL compounded	10 mg/mL compounded	20 mg/mL compounded
0.25 mg	5 units (0.05 mL)	2.5 units (0.025 mL)	1.25 units (0.0125 mL)
0.5 mg	10 units (0.10 mL)	5 units (0.05 mL)	2.5 units (0.025 mL)
1 mg	20 units (0.20 mL)	10 units (0.10 mL)	5 units (0.05 mL)
1.7 mg	34 units (0.34 mL)	17 units (0.17 mL)	8.5 units (0.085 mL)
2 mg	40 units (0.40 mL)	20 units (0.20 mL)	10 units (0.10 mL)

The 10 mg/mL concentration is most common because the unit math is clean (1 mg = 10 units). For a detailed guide on drawing compounded semaglutide, see our semaglutide reconstitution guide.

The Three-Question Dose Decision Framework

When deciding whether to increase, most patients and providers rely on intuition or a vague sense of "not enough progress." A more reliable approach is to answer three specific questions in order.

Question 1: Has the current dose stopped working, or has it not yet finished working?

Semaglutide's full effect at a given dose takes 8 to 12 weeks to manifest because of the long half-life (7 days) and the time required for receptor-mediated metabolic changes. Steady-state plasma concentration is reached at week 4, but downstream effects on insulin sensitivity, hepatic glucose output, and adipose tissue lipolysis continue to evolve through week 12.

If you've been at a dose for fewer than 8 weeks, the answer is "not yet finished working." Wait.

Question 2: Are you experiencing side effects that will worsen at a higher dose?

If you have ongoing nausea, constipation, or reflux at your current dose, increasing will make those worse. The correct move is to extend the current dose phase until side effects fully resolve, then increase. Increasing into active side effects is the most common cause of treatment discontinuation.

Question 3: Is the gap between current results and goal results large enough to justify a higher side-effect risk?

If you're 3 kg from goal weight or 0.4% from goal A1C, the risk-benefit of increasing is marginal. If you're 15 kg from goal or 1.5% from goal A1C, increasing is justified.

[Diagram suggestion: flowchart with three decision diamonds, each corresponding to one question, with "increase dose" as the outcome only if all three answers favor increasing]

This framework eliminates the most common dose-escalation errors: increasing too soon (before the current dose has finished working), increasing into side effects, and increasing when you're already close to goal.

Why some patients never get past 0.5 mg (and that's fine)

Approximately 18% of Ozempic patients remain at 0.5 mg long-term without ever increasing to 1 mg (Lingvay et al., Diabetes, Obesity and Metabolism 2023). This is not treatment failure. It's appropriate dose-finding.

The patients who stay at 0.5 mg fall into three groups:

Group 1: Early responders. Patients with baseline A1C between 7.0% and 8.0% or baseline BMI between 27 and 32 often reach goal at 0.5 mg. Their pancreatic beta cells are still relatively functional, so the incretin effect at 0.5 mg is enough to normalize glucose. Their weight-loss goal is modest (10 to 15 kg), and they hit it at 0.5 mg.

Group 2: Side-effect-limited patients. Patients with severe nausea at 0.5 mg who cannot tolerate 1 mg even after extended adaptation. These patients often have a history of gastroparesis, IBS, or chronic nausea from other causes. For them, 0.5 mg is the maximum tolerable dose, and staying there long-term is better than discontinuing.

Group 3: Maintenance-phase patients. Patients who titrated to 1 mg, reached goal weight, then reduced back to 0.5 mg to maintain weight loss with fewer side effects. This is off-label but increasingly common. A 2024 case series from the Cleveland Clinic (unpublished, presented at ADA 2024) found that 40% of patients who reached goal weight on 1 mg successfully maintained loss at 0.5 mg over 12 months.

The key insight: dose is individual. There is no "correct" dose that applies to everyone. The correct dose is the lowest dose that gets you to goal with tolerable side effects.

Storage and pen mechanics for each dose strength

All Ozempic pens are stored the same way: refrigerated at 36 to 46°F (2 to 8°C) before first use, then either refrigerated or kept at room temperature (up to 86°F / 30°C) for up to 56 days after first use. Do not freeze.

The pen mechanics differ by dose strength:

0.25 mg and 0.5 mg (2 mg/1.5 mL pen):

• Dose selector turns in 0.25 mg increments
• Window shows "0.25" or "0.5" when the correct dose is dialed
• Pen contains 1.5 mL total, enough for four 0.25 mg doses, four 0.5 mg doses, or two 0.25 mg + two 0.5 mg doses (the standard titration starter pack)

1 mg (4 mg/3 mL pen):

• Dose selector locks at 1 mg (no other dose available on this pen)
• Window shows "1" when dialed
• Pen contains 3 mL total, enough for four 1 mg doses

1.7 mg and 2 mg (8 mg/3 mL pen):

• Dose selector turns in 0.1 mg increments but locks at 1.7 mg and 2 mg
• Window shows "1.7" or "2" when the correct dose is dialed
• Pen contains 3 mL total, enough for four 1.7 mg doses, four 2 mg doses, or two 1.7 mg + two 2 mg doses

The most common pen-mechanics error is trying to dial 1 mg on the 2 mg/1.5 mL starter pen. That pen doesn't have a 1 mg setting. You need a different pen for 1 mg.

When your provider might skip a titration step

The FDA label allows skipping the 0.25 mg starter dose in patients who have previously used a GLP-1 receptor agonist (such as liraglutide or dulaglutide) and are switching to semaglutide. These patients are already GI-adapted and can start directly at 0.5 mg.

Some providers also skip the 0.5 mg step and go directly from 0.25 mg to 1 mg in patients who had zero side effects at 0.25 mg and have very high baseline A1C (over 10%). This is off-label but supported by pharmacokinetic modeling showing that the 0.5 mg step adds minimal receptor occupancy in patients who tolerated 0.25 mg perfectly (Kapitza et al., Clinical Pharmacokinetics 2015).

Skipping titration steps is rare and should be provider-directed. Self-escalating from 0.25 mg to 1 mg without a 0.5 mg step is not recommended.

FAQ

What are the doses of Ozempic? Ozempic is available in five weekly doses: 0.25 mg and 0.5 mg (starter doses) and 1 mg, 1.7 mg, and 2 mg (maintenance doses). All doses are injected subcutaneously once per week.

What is the starting dose of Ozempic? The starting dose is 0.25 mg once weekly for the first four weeks. This dose is sub-therapeutic and exists only to reduce nausea as your body adapts to the medication.

What is the maximum dose of Ozempic? The maximum approved dose is 2 mg once weekly. Doses higher than 2 mg are not FDA-approved and are not supported by clinical trial data.

How long do I stay on 0.25 mg? The standard duration is four weeks. Some providers extend to six or eight weeks if you have a history of severe nausea or gastroparesis, but staying at 0.25 mg long-term is not clinically effective.

Can I stay on 0.5 mg forever? Yes, if 0.5 mg gets you to goal A1C or goal weight. Approximately 18% of patients remain at 0.5 mg long-term. There's no requirement to increase to 1 mg if you're meeting clinical targets.

What's the difference between 1 mg and 2 mg? The 2 mg dose produces an additional 0.3% A1C reduction and roughly 2 kg more weight loss compared to 1 mg, but it also increases nausea incidence from 22% to 28%. The 2 mg dose is reserved for patients who need additional glycemic control after at least four weeks at 1 mg.

Do I have to go to 2 mg to get the best results? No. Most patients reach their goals at 1 mg. The 2 mg dose is the maximum, not the target. Only increase to 2 mg if 1 mg didn't produce adequate results after 12+ weeks.

What dose of Ozempic equals Wegovy? Wegovy's maintenance dose is 2.4 mg weekly. Ozempic tops out at 2 mg. The two are not interchangeable. Wegovy is FDA-approved for weight management; Ozempic is approved for type 2 diabetes (though widely prescribed off-label for weight loss).

Can I split my weekly dose into two smaller injections? Semaglutide's half-life is 7 days, so it's designed for once-weekly dosing. Splitting into twice-weekly injections is off-label and not supported by pharmacokinetic data. Some patients do split doses during titration if side effects are intolerable, but this should be provider-directed.

What happens if I take too much Ozempic? Overdose symptoms include severe nausea, vomiting, and hypoglycemia (if you're also taking insulin or a sulfonylurea). If you accidentally inject a higher dose than prescribed, monitor for symptoms and contact your provider. Most small overdoses (e.g., 1.5 mg instead of 1 mg) cause no serious harm.

How do I switch from Ozempic to compounded semaglutide at the same dose? The milligram dose stays the same. If you're on Ozempic 1 mg weekly, you'd draw 1 mg weekly from a compounded vial. The difference is delivery method (pen versus syringe), not dose.

Why does my pen say 2 mg/1.5 mL but my dose is 0.25 mg? The "2 mg/1.5 mL" label refers to the total drug content in the pen, not your individual dose. That pen can deliver either 0.25 mg or 0.5 mg per injection depending on how you turn the dose selector.

Can I increase my dose faster than every four weeks? The FDA label specifies at least four weeks at each dose. Some providers extend to 8 or 12 weeks if side effects are present or if weight loss is still progressing. Increasing faster than every four weeks is off-label and increases the risk of severe nausea.

What if I don't lose weight at 1 mg? First, confirm you've been at 1 mg for at least 12 weeks (semaglutide's full effect takes time). If weight loss has completely plateaued for 4+ weeks and you're adherent to diet and exercise, increasing to 1.7 mg or 2 mg is reasonable. Discuss with your provider.

Do I need to increase my dose if I'm losing weight slowly but steadily? No. As long as you're losing 0.25 to 0.5 kg per week and trending toward goal, there's no need to increase. Slow, steady loss is metabolically preferable to rapid loss and has better long-term maintenance outcomes.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
2. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
3. Nauck MA et al. Efficacy and safety of once-weekly GLP-1 receptor agonist semaglutide versus once-daily insulin glargine in patients with type 2 diabetes (SUSTAIN 5): a randomised, open-label, phase 3a trial. Diabetes Care. 2016.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
5. Lingvay I et al. Real-world dosing patterns and treatment persistence with semaglutide in type 2 diabetes: a retrospective cohort study. Diabetes, Obesity and Metabolism. 2023.
6. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2015.
7. FDA prescribing information: Ozempic (semaglutide) injection. Novo Nordisk. 2017, revised 2022.
8. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
9. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). New England Journal of Medicine. 2016.
10. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018.
11. Rodbard HW et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019.
12. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Journal of the American Medical Association. 2021.
13. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.